Enemark, M. B. H., Sørensen, E. F., Hybel, T. E., Andersen, M. D., Madsen, C., Lauridsen, K. L., Honoré, B., d'Amore, F., Plesner, T. L.
, Hamilton-Dutoit, S. J. & Ludvigsen, M. (2023).
IDO1 Protein Is Expressed in Diagnostic Biopsies from Both Follicular and Transformed Follicular Patients.
International Journal of Molecular Sciences ,
24(8), Article 7314.
https://doi.org/10.3390/ijms24087314
Enemark, M. H., Hemmingsen, J. K., Andersen, M. D., Hybel, T. E., Bjørn, M. E., Josefsson, P. L., Pedersen, L. M., Juul, M. B.
, Pedersen, R. S., Thorsgaard, M.
, Sillesen, I. B., Plesner, T. L.
, Hamilton-Dutoit, S. J., Jensen, P.
, Madsen, C. & Ludvigsen, M. (2024).
Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort.
Blood Cancer Journal,
14(1), 167. Article 167.
https://doi.org/10.1038/s41408-024-01150-3
Enemark, M. H., Hemmingsen, J. K., Jensen, M. L., Kridel, R.
& Ludvigsen, M. (2024).
Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review.
International Journal of Molecular Sciences ,
25(20), Article 11179.
https://doi.org/10.3390/ijms252011179
Enemark, M. H.
, Jensen, M. L., Andersen, M. D., Plesner, T. L., Hamilton-Dutoit, S. & Ludvigsen, M. (2024).
Impact of the Immune Landscape in Follicular Lymphoma: Insights into Histological Transformation in the Rituximab Era.
Cancers,
16(20), Article 3553.
https://doi.org/10.3390/cancers16203553Enemark, M. H., Wolter, K., Hybel, T. E., Andersen, M. D., Sørensen, E. F., Hindkaer, L. M.
, Lauridsen, K. L., Madsen, C., Plesner, T. L., Hamilton-Dutoit, S., Honoré, B. & Ludvigsen, M. (2024).
Differential tumor protein expression at follicular lymphoma diagnosis reveals dysregulation of key molecular pathways associated with histological transformation.
Scientific Reports,
14(1), Article 29962.
https://doi.org/10.1038/s41598-024-81693-4
El-Galaly, T. C., D'Amore, F. A., Brown, P. D. N.
, Christiansen, I., Spect, L., Loft, A.
, Bukh, A., Johnsen, HE., Madsen, C. & Hutchings, M. (2011).
Routine bone marrow biopsy adds little diagnostic information in patients with newly diagnosed Hodgkin lymphoma undergoing PET/CT staging. Blood,
118, 2627.
El-Galaly, T. C. E., D'Amore, F. A., Brown, P. D. N.
, Christiansen, I., Specht, L., Loft, A.
, Bukh, A., Johnsen, H. E., Madsen, C. & Hutchings, M. (2011).
Routine Bone Marrow Biopsy Adds Little Diagnostic Information in Patients with Newly Diagnosed Hodgkin Lymphoma Undergoing PET/CT Staging. Poster session presented at ASH, San Diego, United States.
El-Galaly, T. C., d'Amore, F., Mylam, K. J., de Nully Brown, P.
, Bøgsted, M., Bukh, A., Specht, L., Loft, A.
, Iyer, V., Hjorthaug, K., Nielsen, A. L., Christiansen, I., Madsen, C., Johnsen, H. E. & Hutchings, M. (2012).
Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography-Staged Treatment-Naive Patients With Hodgkin Lymphoma.
Journal of Clinical Oncology,
30(36), 4508-4514.
https://doi.org/10.1200/JCO.2012.42.4036
El-Galaly, T. C., Hutchings, M., Juul Mylam, K., Brown, P. D. N.
, Bukh, A., Kamper, P., Johnsen, H. E. & D'Amore, F. A. (2012).
Clinical Features and Outcome in Newly Diagnosed Hodgkin Lymphoma Patients Presenting with PET/CT-Ascertained Focal Skeletal Lesions.
El-Galaly, T. C., Juul Mylam, K., Brown, P. D. N.
, Bukh, A., Johnsen, H. E., Madsen, C.
, D'Amore, F. A. & Hutchings, M. (2012).
Disease Extent in Newly Diagnosed Hodgkin Lymphoma: A Comparison of CT and PET/CT Staged Patients.
El-Galaly, T. C., Mylam, K., Brown, P., Rossing, M., Gang, A., Haglund, A., Arboe, B., Clausen, M., Jensen, P., Pedersen, M.
, Bukh, A., Amdi Jensen, B., Poulsen, C.
, D'Amore, F. A. & Hutchings, M. (2013).
Patient-reported symptoms are still the single most important factor for detecting lymphoma relapse.
Hematological Oncology,
31.
El-Galaly, T. C., Hutchings, M., Mylam, K. J., de Nully Brown, P.
, Bukh, A., Johnsen, H. E., Kamper, P., Loft, A.
, Iyer, V., Gormsen, L. C., Nielsen, A. L., Bøgsted, M. & d'Amore, F. (2013).
Impact of 18F-FDG PET/CT Staging in Newly Diagnosed Classical Hodgkin Lymphoma: Less Cases with Stage I Disease and More with Skeletal Involvement.
Leukemia & Lymphoma.
https://doi.org/10.3109/10428194.2013.875169
El-Galaly, T., Mylam, K. J., Bøgsted, M., Brown, P., Rossing, M., Gang, A. O.
, Haglund, A., Arboe, B.
, Clausen, M. R., Jensen, P., Pedersen, M.
, Bukh, A., Jensen, B. A., Poulsen, C. B.
, D'Amore, F. & Hutchings, M. (2014).
Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma.
American Journal of Hematology,
89(6), 575-580.
https://doi.org/10.1002/ajh.23688,
https://doi.org/10.1002/ajh.23688
Dybkær, K., Iqbal, J., Zhou, G., Geng, H., Xiao, L.
, Schmitz, A., d'Amore, F. A. & Chan, W. C. (2007).
Genome wide transcriptional analysis of resting and IL2 activated human natural killer cells: Gene expression signatures indicative of novel molecular signaling pathways. BMC Gemomics.
BMC Gemomics,
8(230).
Dupuis, J., Bachy, E., Morschhauser, F., Cartron, G., Fukuhara, N., Daguindau, N., Casasnovas, R. O., Snauwaert, S., Gressin, R., Fox, C. P.
, d'Amore, F. A., Staber, P. B., Tournilhac, O., Bouabdallah, K., Thieblemont, C., André, M., Rai, S., Ennishi, D., Gkasiamis, A. ... Lemonnier, F. (2024).
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.
The Lancet Haematology,
11(6), e406-e414.
https://doi.org/10.1016/S2352-3026(24)00102-9de Leval, L., Alizadeh, A. A., Bergsagel, P. L., Campo, E., Davies, A., Dogan, A., Fitzgibbon, J., Horwitz, S. M., Melnick, A. M., Morice, W. G., Morin, R. D., Nadel, B., Pileri, S. A., Rosenquist, R., Rossi, D., Salaverria, I., Steidl, C., Treon, S. P., Zelenetz, A. D. ... Scott, D. W. (2022).
Genomic profiling for clinical decision making in lymphoid neoplasms.
Blood,
140(21), 2193-2227.
https://doi.org/10.1182/blood.2022015854de Chadarevian, JP., Wolk, JH., Inniss, S., Lischner, HW.
, d'Amore, F. A., Faerber, EN. & Isaacson, GC. (1997).
A newly recognized cause of wheezing:AIDS-related bronchial leiomyomas. Pediatric Pulmonology,
24((2)), 106-10.
D'Amore, F. A., Madsen, J., Nielsen, R., Engebjerg, M., Sørensen, H. & Bukh, A. (2010).
Use of statins and prognosis in patients with CD-20-positive "De novo" diffuse large b cell lymphoma (DLBCL) treated with rituximab containing regimens.
Haematologica, 282.
D'Amore, F. A., Jurczak, W., Skotnicki, A. B., Deptala, A., Windemuth-Kieselbach, C., Lorsbach, M., Delaloye, A. B., Cheolwon, S., Zinzani, P. L., Cacchione, R., Linkesch, W. & Truemper, L. H. (2009).
Consolidation with radioimmunotherapy may prolong survival in first remission of mantle cell lymphoma patients uneligible for stem cell transplantation, an analysis of the international RIT-network.
Blood,
114(22), 22.
D'Amore, F. A., Relander, T., Lauritzsen, GF., Jantunen, E., Hagberg, H., Anderson, H., Holte, H., Østerborg, A., Merup, M., Brown, P. D. N., Østenstad, B., Kuittinen, O., Erlanson, M., Fagerli, UM., Gadeberg, O., Sundström, C., Delabie, J., Ralfkiaer, E., Vornanen, M. & Toldbod, H. (2012).
High-dose chemotherapy and autologous stem cell transplantation in previously untreated peripheral T-cell lymphoma - final analysis of a large prospective multicenter study (NLG-T-01).
Blood,
118, 331.
D'Amore, F. A., Gomes da Silva, M., Leppa, S., Relander, T., Pezzutto, A., Lauritzsen, GF., Weidmann, E., Van Gelder, M., Merup, M., Hagberg, H., Fagerli, UM., Brown, P. D. N., Boye Hansen, P., Mariz, JM., Jankovska, M., Walewski, J., Doorduijn, J., van Hoof, A.
, Christiansen, I. ... Toldbod, H. (2011).
First interim safety analysis of a phase III randomized trial in a newly diagnosed systemic peripheral T-cell lymphoma trated with CHOP chemotherapy with or without alemtuzumab and consolidated by autologous hematopoietic stem cell transplant. Blood,
118, 4110.
D'Amore, F. A., Leppä, S., Gomes da Silva, M., Relander, T., Brown, P. D. N., Weidmann, E., Lauritzsen, GF., Pezzutto, A., Van Hoof, A., Van Gelder, M., Doorduijn, J., Wu, KL., Kluin-Nelemans, JC., Lugtenburg, PJ., Jankovska, M., Merup, M., Fagerli, U.-M., Walewski, J., Hagberg, H. ... Toldbod, H. (2012).
First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma PatientsTreated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy.
Blood,
120(57).
D'Amore, F. A., Relander, T., Lauritzsen, GF., Jantunen, E., Hagberg, H., Anderson, H., Holte, H., Ôsterborg, A., Merup, M., Brown, P. D. N., Kuittinen, O., Erlanson, M., Østenstad, B., Fagerli, U.-M., Gadeberg, OV., Sundström, C., Delabie, J., Ralfkiær, E. M., Vornanen, M. & Toldbod, H. (2012).
Upfront Autologuos Stem Cell Transplantation in Peripheral T-cell Lymphoma (NLG-T-01).
Journal of Clinical Oncology,
30(25), 3093-3099.
D'Amore, F. A., Lauritzsen, G. F., Relander, T., Jantunen, E., Hagberg, H., Anderson, H., Holte, H., Osterborg, A., Merup, M., Brown, P., Kuittinen, O., Erlanson, M., Ostenstad, B., Fagerli, U., Gadeberg, O., Sundstrom, C., Delabie, J., Ralfkiaer, E., Vornanen, M.
& Toldbod, H. (2013).
Late relapses in peripheral T-cell lymphoma patients treated in the nordic NLG-T-01 trial.
Hematological Oncology,
31, 176-177.
D'Amore, F. A., Gaulard, P., Trümper, L., Corradini, P., Kim, W.-S., Specht, L.
& Pedersen, M. B. (2014).
T-cell lymphoma:L ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow up.
Annals of Oncology.
D'Amore, F. A., Jørgensen, J. M., Sillesen, I. B., Segel, E., Bentzen, H. H. N., Thorsgaard, M., Pulcynski, E., Pedersen, B., Gillstrom, D.
, Clausen, M. R., Kamper, P., Silkjær, T., Gormsen, L. C., Leppä, S.
& Toldbod, H. (2014).
Preliminary clinical experience on the efficacy and feasibility of a new combination regimen consisting of pixantrone, etoposide and bendamustine with or without the addition of rituximab in patients with relapsed/refractory aggressive non-hodgkin lymphomas.
Blood,
124(21).
D'Amore, F. A., Relander, T., Lauritzen, G. F., Jantunen, E., Mannisto, S., Meyer, P., Ellin, F.
, Pedersen, M. B. & Toldbod, H. (2016).
Hematopoietic stem-cell transplantation in peripheral T-cell lymphomas. In
Hematopoietic cell transplants - Concepts, controversies and future directions (Vol. 37, pp. 343-347). Cambridge University Press.
https://doi.org/10.3760/cma.j.issn.0253-2727.2016.04.020
d'Amore, F. A., Johansen, P., Houmand, A., Weisenburger, DD. & Mortensen, L. (1996).
Epstein-Barr virus genome in non-Hodgkin's lymphomas occuring in immunocompetent patients: highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Danish Lymphoma Study Group, LYFO. Blood,
87((3)), 1045-55.
d'Amore, F. A., Stribley, JA., Ohno, T., Wu, G., Wickert, RS., Delabie, J., Hinrichs, SH. & Chan, W. C. (1997).
Molecular studies on single cells harvested by micromanipulation from archival tissue sections previously stained by immunohistochemistry or nonisotopic in situ hybridization.
Laboratory Investigation,
76((2)), 219-24.
d'Amore, F., Radford, J., Relander, T., Jerkeman, M., Tilly, H., Osterborg, A., Morschhauser, F., Gramatzki, M., Dreyling, M., Bang, B. & Hagberg, H. (2010).
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
British Journal of Haematology, Supplement,
150(5), 565-73.
https://doi.org/10.1111/j.1365-2141.2010.08298.x
d'Amore, F., Gaulard, P., Trümper, L., Corradini, P.
, Kim, W.-S., Specht, L., Bjerregaard Pedersen, M., Ladetto, M. & ESMO Guidelines Committee (2015).
Peripheral T-cell Lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of Oncology,
26 Suppl 5, v108-15.
https://doi.org/10.1093/annonc/mdv201
d'Amore, F., Federico, M., de Leval, L., Ellin, F., Hermine, O., Kim, W. S., Lemonnier, F., Vermaat, J. S. P., Wulf, G., Buske, C., Dreyling, M., Jerkeman, M., ESMO Guidelines Committees & EHA Guidelines Committees (2025).
Peripheral T- and natural killer-cell lymphomas: ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-up ☆.
Annals of Oncology,
36(6), 626-644.
https://doi.org/10.1016/j.annonc.2025.01.023
d'Amore, F., Federico, M., de Leval, L., Ellin, F., Hermine, O., Kim, W. S., Lemonnier, F., Vermaat, J. S. P., Wulf, G., Buske, C., Dreyling, M., Jerkeman, M. & the ESMO and EHA Guidelines Committees (2025).
Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment, and follow-up.
HemaSphere,
9(5), Article e70128.
https://doi.org/10.1002/hem3.70128
Coiffier, B., Federico, M., Caballero, D., Dearden, C., Morschhauser, F., Jäger, U., Trümper, L., Zucca, E., Gomes da Silva, M., Pettengell, R., Weidmann, E.
, d'Amore, F., Tilly, H. & Zinzani, P. L. (2014).
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Cancer Treatment Reviews,
40(9), 1080-1088.
https://doi.org/10.1016/j.ctrv.2014.08.001Clausen, M. R., Leppa, S., Brown, P. D. N., Goerloev, J. S., Panny, M., Willenbacher, W.
, Sillesen, I. B., Segel, E., Bentzen, H. H. N., Thorsgaard, M.
, Pulczynski, E. J., Kamper, P., Gormsen, L. C., Mortensen, J., Lauritzsen, G., Relander, T.
& d'Amore, F. (2016).
The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial).
Blood,
128(22), 1782-1782.
https://doi.org/10.1182/blood-2016-07-726505
Clausen, M. R., Ulrichsen, S. P., Larsen, T. S., Poulsen, C. B., Tojaga, S., Pedersen, P. T., Madsen, J., Pedersen, R. S., Josefsson, P. L., Gørløv, J. S.
, Nørgaard, M. & d'Amore, F. (2019).
Depth of neutrophil nadir after first cycle of R-CHOP predicts outcome in diffuse large B-cell lymphoma - a nationwide population-based cohort study.
Leukemia & Lymphoma,
60(8), 1950-1957.
https://doi.org/10.1080/10428194.2018.1554863
Clausen, M. R., Maurer, M. J.
, Ulrichsen, S. P., Larsen, T. S., Himmelstrup, B., Rønnov-Jessen, D., Link, B. K., Feldman, A. L., Slager, S. L., Nowakowski, G. S., Thompson, C. A., Pedersen, P. T., Madsen, J.
, Pedersen, R. S., Gørløv, J. S., Cerhan, J. R.
, Nørgaard, M. & D’amore, F. (2019).
Pretreatment hemoglobin adds prognostic information to the nccn-ipi in patients with diffuse large b-cell lymphoma treated with anthracycline-containing chemotherapy.
Clinical Epidemiology,
11, 987-996.
https://doi.org/10.2147/CLEP.S219595